Form 8-K - Current report:
SEC Accession No. 0001193125-26-157140
Filing Date
2026-04-15
Accepted
2026-04-15 16:35:50
Documents
19
Period of Report
2026-04-14
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d283634d8k.htm   iXBRL 8-K 31001
2 EX-1.1 d283634dex11.htm EX-1.1 194363
3 EX-5.1 d283634dex51.htm EX-5.1 8740
4 EX-99.1 d283634dex991.htm EX-99.1 7560
5 EX-99.2 d283634dex992.htm EX-99.2 7756
9 GRAPHIC g283634dsp47.jpg GRAPHIC 5284
10 GRAPHIC g283634g0415103446194.jpg GRAPHIC 5860
11 GRAPHIC g283634g0415103559226.jpg GRAPHIC 5860
12 GRAPHIC g283634g0415111622762.jpg GRAPHIC 3203
  Complete submission text file 0001193125-26-157140.txt   453386

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA allo-20260414.xsd EX-101.SCH 3169
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE allo-20260414_lab.xml EX-101.LAB 17234
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE allo-20260414_pre.xml EX-101.PRE 10805
22 EXTRACTED XBRL INSTANCE DOCUMENT d283634d8k_htm.xml XML 3518
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38693 | Film No.: 26864571
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)